{"id":127911,"title":"Genflow Biosciences (LON: GENF) Shares Jump 100% After Alternative Share Placement","publisher":"Share Talk","author":"sharetalk","published":"2025-10-09T08:22:25+00:00","modified":"2025-10-09T08:22:25+00:00","canonical_url":"https://www.share-talk.com/genflow-biosciences-lon-genf-shares-jump-100-after-alternative-share-placement/","markdown_url":"https://www.share-talk.com/genflow-biosciences-lon-genf-shares-jump-100-after-alternative-share-placement.md","json_url":"https://www.share-talk.com/genflow-biosciences-lon-genf-shares-jump-100-after-alternative-share-placement.json","category":"Health","categories":["Health","Healthcare","Pharmaceutical"],"tags":["ageing","cell","Dr. Eric Leire","GENE","Gene Therapy","GENF","Genflow Biosciences","Genflow Biosciences Plc","IPO","laboratory","London Stock Exchange","Longevity","Patent","process","Share Talk","therapies","University of Rochester"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2025/02/Genflow-Biosciences.webp?fit=1200%2C800&ssl=1","format":"news","language":"en-GB","content":"**Genflow Biosciences Raises £440,000 Through Alternative Share Placement.**\n\n[Genflow Biosciences Plc](https://www.investegate.co.uk/announcement/rns/genflow-biosciences--genf/update-equity-issue-and-pdmr-notification-/9159597)announced that it has **terminated** the previously announced transaction from **October 2, 2025**, and instead completed an **alternative fundraising**, raising **£440,000 before expenses**.\n\nThe funding was secured through the **allotment of 40,000,000 new ordinary shares** at **1.1 pence per share** to **Eric Leire**. Of these, **35,454,546 shares** will be transferred to a **consortium of existing shareholders**, with **Leire retaining 4,545,454 shares**.\n\nBoth the purchasers and Leire will receive **warrants on a one-for-one basis**, exercisable at **1.2 pence per share** for **24 months**.\n\nFollowing admission, the company’s **issued share capital and voting rights** will total **493,547,942 ordinary shares**. Admission to the **FCA Official List** and trading on the **London Stock Exchange** is expected at around **8:00 a.m. on October 16, 2025**.\n\n**Dr. Eric Leire, CEO of Genflow, commented:** “We would like to express our sincere gratitude to our historical shareholders for their continued confidence and commitment to Genflow’s vision. Their ongoing support reflects a shared belief in our mission.  With this additional capital, Genflow is able to deliver on our near-term objectives.”\n\n**About Genflow Biosciences**\n\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow’s lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow’s 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit [www.genflowbio.com](http://www.genflowbio.com/)  and follow the Company on [LinkedIn](https://www.linkedin.com/company/genflow-biosciences/?viewAsMember=true) and [X](https://x.com/genflowbio)."}